Introduction
7. Digital subtraction angiography (DSA) is a fluoroscopy technique that uses a contrast agent and no tracer material. This should be considered when comparing DSA with Positron emission tomography (PET).
8. Although the development in MPI holds out the prospect of real-time imaging for MPI guided interventions, we should not create the impression that MPI is already a real-time imaging modality with instant image acquisition and reconstruction yet. 9. Typo: "Thus, it is often used when imaging dense material such as bone structures." could be erased.
10. Typo: "… containing mostly fat and water." could be erased.
Basic Imaging Principles
11. While it is true that in many actual implemented scanner systems the excitation field and the drive field are implemented using the same coils, it might be helpful for some readers, with no previous knowledge concerning MPI, to separate them. Using the term "excitation field"
for the varying magnetic field that excites the SPIONs and the term "drive filed" for the fields that enable the movement of the FFP or FFL respectively could help.
12. Some elaboration (more than in the caption of figure 1) on the nonlinearity of the magnetization curve of SPIONs and its importance for MPI could be useful.
13. Typo: "…called drive field HD(t), causes the magnetic moment to flip,….". 14. Typo: "In order to spatially encode the particle signal……". 15. Typo: "…Hs(i) is high enough to inhibit/negate the effect of the….".
MPI in Vascular Medicine
16. Typo: "…DSA, wich utilises ionizing radiation." ("in the catheter laboratory ." could be erased).
Visualization of Instruments for Cardiovascular Interventions
17. The paragraph about the heating of interventional instruments in MPI scanners is a bit ambiguous. It is not the SPION-coating that is responsible for the occurrence of heating. The tested devices had no such coating. The "signal" was generated by the devices and was not useable for MPI. It is the material and geometry that determined the heating (of up to 85°C not 80°C). 
Thermo

Comments to Authors:
General comment:
This review reports on the new and innovative imaging technique "Magnetic Particle Imaging" (MPI) and its possible role in diagnostic imaging of the vascular system and vascular disease/injury related disorders, its possible role in image guided vascular therapy, and its possible role in various other biomedical applications.
The review gives a rather optimistic perspective on the topic of MPI. MPI is in a very early phase of development. Therefore currently it is not sure if, this technique will ever be available for clinical use. Furthermore, the topic of appropriate tracers for MPI is dealed with in a simplifying way.
The topic of a possible role in supporting decision making in vascular therapy/surgery could be emphasized a little bit more.
The authors might think about reducing the description of theoretical and technical details of MPI technology.
Language editing seems to be necessary.
Title: Please put emphasis on "possible future clinical applications" Abstract:
Second para: It is not possible to make a general statment on the possible clinical applicabiliy of MPI tracers. Each individual product has to be developed as a parenteral drug.
Key words:
Should include "magnetic particle imaging" Introduction: statements on CT: Only partially true. CT is the workhorse in diagnostic in vivo imaging with the indications in musculoskelettal imaging, but also thoracic/lung imaging, abdminal imaging, and also vascular imaging imcluding cardiac imaging, and head and neck imaging.
Statements on MRI: Wrong -signal intensities and contasts mainly depend on proton T1-and T2-relaxation times and only in minor part on proton density. Additionally images can be generating, in which signal intensities and contrast depend on flow or diffusion. Again: There are currently no approved applications of magnetic nanoparticles for diagnostic imaging or for use as drug carriers. The only approved indication is use of magnetic nanoparticles as medical device for magnetic hyperthermia.
page 6, line 1: "… used as a tracer …": experimentally or clinically? please be specific which each of such a statement.
page 6, line 7: " … nephrotoxic …" and so on: Please do not be overoptimistic regarding MNPs for clinical use. The coating material can cause allergic reactions, including those with fatal outcome (see ferumoxytol, clinically used for parenteral iron replacement therapy).
Please comment on this topic.
Page 6, line 10: "gold standard" -please be specific: for experimental use only.
Page 6, line 11: Resovist: There is no approval any more.
Page 6, line 13: "off-label" -The term "off-label" does only make sense for clinical use. That is not the case for MPI. Reviewers' comments:
Reviewer #1: This work is a very comprehensive review article.
Thank you very much for reviewing our manuscript. We appreciate your comments and recommendations, which have improved our article.
We revised our work carefully and hope that we could clarify the issues you made with some additional explanations. Please find below our answers in detail.
Recommendations:
General recommendations 1. As the term for the magnetic tracer material that has been adopted by the "MPI-Community" is superparamagnetic iron oxide nanoparticles (SPIONs or SPIOs) it might be appropriate to replace magnetic nanoparticle (MNP) with either SPION or SPIO.
We appreciate the comment. Since we first introduce the MPI nanoparticle tracer as superparamagnetic iron oxide nanoparticles in 2.4, we Bakenecker et al.: MPI in vascular medicine V used the more general term "magnetic nanoparticles" before and, therefore, throughout the whole article. This also gives us the possibility to use the abbreviation in contexts where indeed MNPs that are not SPIONs can be used in an MPI applications such as magnetic manipulation. Thus, we emphasize that we are not strictly limited to particles that can be visualized with MPI.
2. The rather general term "interventional imaging" could be replaced with more specific terms (like cardiovascular imaging, real-time imaging etc.) where appropriate.
Thank you for the comment. The term "interventional imaging" refers to the imaging technique to be used during an operation. In our opinion, the term is therefore appropriate. MPI is an imaging modality suitable for cardiovascular imaging plus it is a real-time imaging modality plus it is radiation free and all these features together make MPI suitable as an image guidance for interventions.
3. Somehow the impression is created that all magnetic nanoparticle are biocompatible. Although that is true for the established gold-standard for MPI (Resovist), new SPIONs will have to be designed and tested accordingly, to ensure biocompatibility (no oxidative stress, inflammatory response etc.). This safety consideration should be made clear.
Thank you for this annotation. We hope it is now clearer that MNPs can be biocompatible, however, that needs to be approved. Hence, we added in section 2.3 "The biocompatibility of the tracer material can be achieved by a biocompatible coating of the MNPs (see section 2.4).
However, for the use in clinical routine the tracer material needs to be officially approved" In section 2.4, we added "In future, optimized tracer materials need to be evaluated and approved for clinical applications." Here, we also pointed out that Resovist was approved as a contrast agent for MRI, which is nowadays used for experimental and preclinical MPI applications. Thank you. The mistake is corrected.
5. Typo: "In the first part of this article, the basic principle of MPI will be explained and a short overview of the principles of the generation and spatial encoding of the tracer-signal will be given."
Thank you. The mistake is corrected.
6. Typo: "… with an emphasis on vascular imaging. (such as … could be erased).
In our opinion, the second half of the sentence "such as the use of MPI during cardiovascular interventions by visualizing the instruments"
gives some more details about what the reader can expect in this research field.
1 Introduction 7. Digital subtraction angiography (DSA) is a fluoroscopy technique that uses a contrast agent and no tracer material. This should be considered when comparing DSA with Positron emission tomography (PET).
It is unfortunate, that this is not clear. We have re-read the section and have adapted the following part: "The drawback of this technique is that ionizing radiation is needed and the iodine-based tracer material can be nephrotoxic…" to "The drawback of these techniques are that ionizing radiation is needed and the iodine-based contrast agent material can be nephrotoxic…". However, this seems the only part where we have used the wrong term. If you have more concerns about this part, please let us know.
8. Although the development in MPI holds out the prospect of real-time imaging for MPI guided interventions, we should not create the impression that MPI is already a real-time imaging modality with instant image acquisition and reconstruction yet.
We appreciate your concern. However, for small volumes, MPI is able to image a 3D volume within 20 ms and the reconstruction is fast enough to show a reconstructed image with negligible time delay as we show with references in later sections. Especially, the applications performed with MPI shown in [WGR09] demonstrate that this statement holds. Thus, we think it is reasonable to state that MPI is a real-time imaging modality in the introduction to get the reader's attention and describe the restrictions in the specific sections.
9. Typo: "Thus, it is often used when imaging dense material such as bone structures." could be erased.
Thank you, we erased the second part of the sentence.
2 Basic Imaging Principles 11. While it is true that in many actual implemented scanner systems the excitation field and the drive field are implemented using the same coils, it might be helpful for some readers, with no previous knowledge concerning MPI, to separate them. Using the term "excitation field"
We thought it is easier to explain two fields instead of explaining first three fields and then why it is not necessary to use an excitation and drive field. We checked the section for consistency and added the following sentences, which clarifies that the FFP/FFL movement is generated by the drive field, which also flips the magnetic moment. "Due to the fact that the excitation of the particles is established by the drive field, this field is also referred to as excitation field." And "A sufficiently large amplitude of the drive field leads to a significant movement of the FFP or FFL along a line. A drive field applied in two or three dimensions enables a movement of the FFP or FFL in a plane or volume, respectively" 12. Some elaboration (more than in the caption of figure 1) on the nonlinearity of the magnetization curve of SPIONs and its importance for MPI could be useful.
Thank you for the comment. We added the following in section in 2.1: "A further increase of the applied magnetic field strength has therefore no impact on the magnetization. This behavior results in a characteristic nonlinear magnetization curve as a function of the magnetic field strength. Hence, the temporal evolution of the magnetization has a plateau at its minimum and maximum. That means that the magnetic moments of the MNPs flip with the same frequency as the drive field, but the temporal evolution of the magnetization is modulated" 13. Typo: "…called drive field HD(t), causes the magnetic moment to flip,….".
14. Typo: "In order to spatially encode the particle signal……".
15. Typo: "…Hs(i) is high enough to inhibit/negate the effect of the….".
MPI in Vascular Medicine
Thank you, we erased it.
Visualization of Instruments for Cardiovascular Interventions
17. The paragraph about the heating of interventional instruments in MPI scanners is a bit ambiguous. It is not the SPION-coating that is responsible for the occurrence of heating. The tested devices had no such coating. The "signal" was generated by the devices and was not useable for MPI. It is the material and geometry that determined the heating (of up to 85°C not 80°C).
Thank you for pointing out this issue. We changed the corresponding paragraph from "For safety reasons, the heating of the instruments needs to be considered, which can occur due to the high frequency of the drive fields and the resulting eddy currents within the instruments. The review gives a rather optimistic perspective on the topic of MPI. MPI is in a very early phase of development. Therefore currently it is not sure if, this technique will ever be available for clinical use.
Furthermore, the topic of appropriate tracers for MPI is dealed with in a simplifying way.
Thank you very much for reviewing our manuscript. We appreciate your comments and edited the article carefully. We hope that we could clarify the technical aspects you mentioned, which were not clearly understandable and put effort in improving the language. Since your annotations are critical regarding MPI in clinical use and especially the approval of the tracer material we added a couple of statements to make clear that MPI is a promising method for vascular medicine, but is not yet in clinical use and several issues, such as upscaling and safety, need to be faced. Further we emphasized that the approval of the tracer material is an open task, but please find our answers to your annotations in detail below.
Title: Please put emphasis on "possible future clinical applications"
We changed "In the last part, a variety of different clinical application scenarios will be presented with an emphasis on vascular imaging" to "In the last part, a variety of possible future clinical applications will be presented with an emphasis on vascular imaging" to point out that MPI is not in clinical use yet, but we will discuss future possibilities. However, we do not want to change the title of the article since the whole article is not only about future clinical applications, but deals with MPI in general with an emphasis on MPI for vascular imaging.
Abstract:
We changed "… that the used tracer material is biocompatible" to " that the used tracer material can be made biocompatible". In section 2.3 and 2.4 we also pointed out how MNPs can be made biocompatible, that Resovist was an approved tracer material for MRI liver imaging, but if MPI goes the step towards clinical investigation the used tracer material needs to be approved, which is not yet the case since all investigations are in vitro or preclinical so far.
Key words:
Should include "magnetic particle imaging"
Thank you for this advice. We added "Magnetic Particle Imaging" and "MPI" as well as "vascular imaging" to the list of key words. We were not sure if we have to add those keywords, since they are part of the title.
Introduction: statements on CT: Only partially true. CT is the workhorse in diagnostic in vivo imaging with the indications in musculoskelettal imaging, but also thoracic/lung imaging, abdminal imaging, and also vascular imaging imcluding cardiac imaging, and head and neck imaging.
We wanted to emphasize that the great advantage of MPI compared to CT is that no ionizing radiation is needed. That should not mean that CT is not suitable for vascular imaging, since as you said it is nowadays the "workhorse", but we want to point out that MPI can be an alternative in future. Since we did not aim at keeping back that CT is suitable for vascular imaging we added: "CT is widely used for head and neck imaging and is especially suitable for vascular and cardiac imaging." and "The continuous development of all these techniques has taken in vivo diagnostics a decisive step forward" Statements on MRI: Wrong -signal intensities and contasts mainly depend on proton T1-and T2-relaxation times and only in minor part on proton density. Additionally images can be generating, in which signal intensities and contrast depend on flow or diffusion.
Thank you for pointing out this issue. We changed "proton density" to "proton relaxation times" and added: "Further, MRI can provide information about flow and diffusion"
Especially vascular surgeons are very well aware of the strength of CT and MRI in cardiovascular imaging (CTA, MRA). Therefore the authors should not give the impression, that CT and MRI are not suited for clinical diagnostic vascular imaging.
As we said before, we want to present a future alternative method and we want to emphasize and explain why it might be worth thinking about using MPI for vascular imaging. Today, CT and MRI are the methods of choice for cardiovascular interventions. We hope that by adding the sentence "The continuous development of all these techniques has taken in vivo diagnostics a decisive step forward" we could address your concern. statement on DSA: More precisely -the lumen of the blood vessels is visulaized.
Thank you for your comment. We changed "To visualize blood vessels, Digital Subtraction Angiography (DSA) …." to "To visualize the lumen of blood vessels, Digital Subtraction Angiography (DSA) …." Statements on MPI: "…. especially for vascular interventions": Please be a little bit more precise, e.g.: applications in diagnostic vascular in vivo imaging and in imaging guided vascular interventions.
Thank you for your comment. We corrected this sentence by replacing "vascular interventions" with "for applications in diagnostic vascular in vivo imaging and imaging guided vascular interventions". statements on MNPs: (" ….biocompatible…") This statement is not true in general. Furthermore, if the authors speculate on use in humans, the term "biocompatible" is meaningless in the context of regulatories. Here, or lateron, the authors should clarify, that there is no approved tracer (based on magnetic iron oxide nanoparticles) available for diagnostic imaging. The authors should also discuss, that, even if a tracer would be approved for human MPI, institutions like the IQWiG (in Germany) will eveluate the added value of such a new diagnostic test (MPI in combination with the tracer) compared to established vascular imaging/intervention techniques, before reembursement of the costs by the insurances will be possible.
We added "In future, optimized tracer materials need to be evaluated and approved for clinical applications." in section 2.4.
